Linnaeus Bioscience

Linnaeus Bioscience is a specialized CRO founded in 2018, focusing on the urgent global challenge of antimicrobial resistance (AMR). Its core offering is a revolutionary, AI-powered microscopy platform called Bacterial Cytological Profiling, which rapidly identifies and characterizes the mechanism of action of novel antibacterial compounds. With a leadership team boasting deep expertise in microbiology, drug discovery, and medicinal chemistry, the company partners with pharmaceutical and biotech firms to streamline and de-risk early-stage antibiotic R&D. Its business model is centered on providing high-value research services and collaborative partnerships rather than developing its own therapeutic pipeline.

Bacterial Cytological Profiling (BCP) - a high-content fluorescence microscopy platform combined with proprietary AI software to rapidly identify and characterize the mechanism of action of novel antibacterial compounds.

Competes with other CROs offering phenotypic screening and traditional microbiology services. Faces competition from alternative technologies for mechanism-of-action studies, such as transcriptomic profiling and proteomics. Its unique differentiation is the combination of high-resolution live-cell imaging with AI-driven phenotypic fingerprinting.